A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy

被引:11
|
作者
Adhikarla, Vikram [1 ]
Awuah, Dennis [2 ]
Brummer, Alexander B. [1 ]
Caserta, Enrico [3 ]
Krishnan, Amrita [2 ]
Pichiorri, Flavia [3 ]
Minnix, Megan [4 ]
Shively, John E. [4 ]
Wong, Jeffrey Y. C. [5 ]
Wang, Xiuli [2 ]
Rockne, Russell C. [1 ]
机构
[1] City Hope Natl Med Ctr, Div Math Oncol, Dept Computat & Quantitat Med, Beckman Res Inst,Natl Med Ctr, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Hematol Malignancies Translat Sci, Beckman Res Inst, Natl Med Ctr, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Dept Mol Imaging & Therapy, Natl Med Ctr, Duarte, CA 91010 USA
[5] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA
基金
美国国家卫生研究院;
关键词
CAR-T; targeted radionuclide therapy; TRT; mathematical model; multiple myeloma; immunotherapy; daratumumab; CS1; combination therapy; alpha particle therapy; actinium-225; IMMUNOTHERAPY;
D O I
10.3390/cancers13205171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
    Masoumi, Javad
    Jafarzadeh, Abdollah
    Abdolalizadeh, Jalal
    Khan, Haroon
    Philippe, Jeandet
    Mirzaei, Hamed
    Mirzaei, Hamid Reza
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (07) : 1721 - 1739
  • [2] Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
    Hosen, Naoki
    CANCERS, 2019, 11 (12)
  • [3] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Wang, Zehua
    Chen, Chen
    Wang, Lei
    Jia, Yongxu
    Qin, Yanru
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma
    Sterner, Robert C.
    Sterner, Rosalie M.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy
    Yang, Yan
    Zhou, Jing
    Cao, Cong
    Cai, Panpan
    Wang, Xinxuan
    Chang, Chun
    Wang, Jingxuan
    Zhang, Qingyuan
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (11) : 7310 - 7322
  • [6] Chimeric antigen receptor T cell therapy for multiple myeloma
    Hasegawa, Kana
    Hosen, Naoki
    INFLAMMATION AND REGENERATION, 2019, 39 (1)
  • [7] Chimeric antigen receptor T cell therapy for multiple myeloma
    Kana Hasegawa
    Naoki Hosen
    Inflammation and Regeneration, 39
  • [8] Biomarkers in individualized management of chimeric antigen receptor T cell therapy
    Du, Mengyi
    Hari, Parameswaran
    Hu, Yu
    Mei, Heng
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [9] Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure
    Holland, Elizabeth M.
    Yates, Bonnie
    Steinberg, Seth M.
    Yuan, Constance M.
    Wang, Hao-Wei
    Annesley, Colleen
    Shalabi, Haneen
    Stroncek, David
    Fry, Terry J.
    Krueger, Joerg
    Jacoby, Elad
    Hsieh, Emily
    Bhojwani, Deepa
    Gardner, Rebecca A.
    Maude, Shannon L.
    Shah, Nirali N.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (09): : 574.e1 - 574.e10
  • [10] Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
    Han, Xiao
    Wang, Yao
    Wei, Jianshu
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)